Olaparib +/- Bevacizumab for Ovarian Cancer
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial examines the effectiveness of the drug olaparib when taken for one year versus two years, with or without the addition of bevacizumab, in treating advanced ovarian cancer. Olaparib may prevent cancer cell growth by blocking certain enzymes, while bevacizumab cuts off the blood supply tumors need to grow. The trial targets individuals with stage III or IV ovarian cancer who have specific genetic changes, such as BRCA mutations. It suits those who have completed initial chemotherapy and currently show no signs of cancer progression. As a Phase 3 trial, this study represents the final step before potential FDA approval, offering participants a chance to contribute to advancing treatment options.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you cannot use strong or moderate CYP3A inducers (a type of drug that affects how your body processes certain medications). It's best to discuss your current medications with the trial team.
Is there any evidence suggesting that this trial's treatments are likely to be safe?
Research has shown that using olaparib with bevacizumab is generally safe. In a study with older patients, this treatment did not significantly change their quality of life, indicating it was well-tolerated. Another study found that adding olaparib to bevacizumab helped patients live longer without their cancer returning. Although all treatments can have side effects, evidence suggests this combination is usually safe for patients with advanced ovarian cancer.12345
Why are researchers excited about this trial's treatments?
Researchers are excited about olaparib and bevacizumab for ovarian cancer because they work in a novel way compared to traditional chemotherapy options. Olaparib is a PARP inhibitor, which means it targets and disrupts cancer cells' ability to repair their DNA, potentially leading to their death. Bevacizumab complements this by blocking the blood vessels tumors need to grow, cutting off their nutrient supply. Together, they offer a targeted approach that could enhance effectiveness and reduce reliance on broad-spectrum chemotherapy, which often comes with significant side effects.
What evidence suggests that this trial's treatments could be effective for ovarian cancer?
Research has shown that using olaparib with bevacizumab may effectively treat advanced ovarian cancer, particularly in patients with specific genetic traits like BRCA mutations or HRD (a type of DNA repair issue). This trial will evaluate the combination of olaparib and bevacizumab. Studies have found that this combination helps patients live longer without their cancer worsening compared to using bevacizumab alone. Specifically, one study revealed that 67% of patients taking both drugs did not see their cancer grow or return, while only 30% of those taking bevacizumab with a placebo experienced the same result. Additionally, this combination has been linked to a significant improvement in overall survival for patients with HRD, reducing the risk of death by 38%. This demonstrates its potential as an effective treatment for advanced ovarian cancer.23678
Who Is on the Research Team?
Ying Liu
Principal Investigator
NRG Oncology
Are You a Good Fit for This Trial?
This trial is for patients with advanced ovarian cancer (stages III or IV) that's BRCA 1/2 mutated or homologous recombination deficient. Participants must have completed 4-9 cycles of platinum-based chemotherapy and undergone surgery to remove the tumor. They can't join if they've had certain treatments that could interfere with the study.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive olaparib for 1 or 2 years, with optional bevacizumab for up to 1 year
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Bevacizumab
- Olaparib
Trial Overview
The trial is testing how long to give Olaparib, a drug that blocks enzymes tumors need to grow, either one year or two years, and whether adding Bevacizumab, which stops blood vessel growth in tumors, makes a difference in treatment effectiveness.
How Is the Trial Designed?
2
Treatment groups
Experimental Treatment
Active Control
Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients may also receive bevacizumab IV on day 1 of each cycle. Cycles of bevacizumab repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and CT and/or MRI throughout the study.
Patients receive olaparib PO BID on days 1-21 of each cycle. Cycles repeat every 21 days for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients may also receive bevacizumab IV on day 1 of each cycle. Cycles of bevacizumab repeat every 21 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients also undergo blood sample collection and CT and/or MRI throughout the study.
Find a Clinic Near You
Who Is Running the Clinical Trial?
NRG Oncology
Lead Sponsor
National Cancer Institute (NCI)
Collaborator
Citations
Cost-Effectiveness Analysis of Olaparib in Combination ...
Maintenance therapy with olaparib plus bevacizumab demonstrated a clinically significant benefit in PFS compared with bevacizumab monotherapy in ...
Olaparib plus Bevacizumab as First-Line Maintenance in ...
Olaparib has shown significant clinical benefit as maintenance therapy in women with newly diagnosed advanced ovarian cancer with a BRCA mutation.
Results of LYNPARZA: advanced ovarian cancer
168 out of 255 patients on LYNPARZA + bevacizumab did not see their cancer grow or return compared with 40 out of 132 patients on bevacizumab + placebo. 67%.
final overall survival results from the PAOLA-1/ENGOT ...
Conclusions. Olaparib plus bevacizumab provided clinically meaningful OS improvement for first-line patients with HRD-positive ovarian cancer.
LYNPARZA® (olaparib) in Combination With ... - Merck.com
These latest results at the five-year landmark demonstrate that olaparib with bevacizumab reduces the risk of death by 38% in HRD-positive ...
Safety and quality of life with maintenance olaparib plus ...
Conclusion: Among older patients in PAOLA-1, olaparib plus bevacizumab had a manageable safety profile and no adverse impact on QoL. Additional ...
Efficacy and safety of maintenance olaparib ...
The phase III PAOLA-1/ENGOT-ov25 study (NCT02477644) showed that addition of olaparib to bevacizumab maintenance improved progression-free survival (PFS) in ...
Safety and quality of life with maintenance olaparib plus ...
Among older patients in PAOLA-1, olaparib plus bevacizumab had a manageable safety profile and no adverse impact on QoL. Additional data are ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.